March 8th 2024
On March 08, 2024, the FDA approved semaglutide 2.4 mg (Wegovy) to reduce cardiovascular risk in adults with obesity or overweight and heart disease based on the SELECT trial.
Pharmacist-Led Interventions Can Improve HbA1c in Underserved Communities
September 29th 2023A study from UCLA suggests a pharmacist-led intervention contributed to improved HbA1c in Hispanic adults with type 2 diabetes management, underlining its potential to enhance outcomes in underserved populations.
Tirzepatide Bests Semaglutide For A1c, Weight Loss in Indirect Comparison of Clinical Trial Data
September 25th 2023A network meta-analysis suggests tirzepatide may be more effective than semaglutide in reducing HbA1c and body weight in type 2 diabetes but may increase gastrointestinal adverse events, especially at higher doses.
Type 1 and Type 2 Diabetes Incidence Increased During COVID-19 Pandemic
September 21st 2023An analysis of patient data from a health system in southern California suggests both type 1 and type 2 diabetes rates rose among younger populations during the COVID-19 pandemic, affecting non-Hispanic Black and Hispanic youth most significantly.
Study Examines Prevalence, Drivers of Racial Disparities in T2D Following Gestational Diabetes
September 11th 2023An analysis of data from more than 20,000 women in the New York City A1c registry details the prevalence of and drivers behind racial/ethnic disparities in the incidence of type 2 diabetes following gestational diabetes mellitus.
Semaglutide Could Eliminate Need for Insulin in Type 1 Diabetes
September 6th 2023A case series of 10 patients with newly diagnosed type 1 diabetes provides insight into the beneficial effects of off-label semaglutide use on insulin use, HbA1c, and fasting C-peptide levels among this patient population.
Diabetes Dialogue: Addressing Health Disparities with Diabetes Technology, with Etty Vider, PharmD
August 31st 2023During this episode, hosts are joined by Etty Vider, PharmD, for a nuanced discussion surrounding leveraging diabetes technology to improve care for people with diabetes, including exploring strategies for improving the utilization of diabetes technology, the role of primary care in adoption of these technologies, and how improved uptake correlates to improved outcomes.
Bempedoic Acid Proves Cardiovascular Benefit Across Glycemic Spectrum in New Analysis
August 30th 2023A prespecified analysis of the CLEAR Outcomes trial assessing outcomes according to glycemic status suggests bempedoic acid provided similar relative benefits across the glycemic spectrum, but the greatest absolute benefits were observed in patients with diabetes.
Diabetes Dialogue: The Role of Nutrition in Diabetes Management, with Dawn Noe, RDN, LD
August 22nd 2023In this episode, Isaacs and Bellini sit down with Dawn Noe, RDN, LD, for a discussion surrounding her journey into diabetes care, the importance of individualizing nutrition in diabetes management, and the sessions she led and moderated at ADCES 2023.
Study Estimates More than 90 Million US Adults Could Benefit from Semaglutide 2.4 mg
August 21st 2023Using data and eligibility criteria from the STEP 1 trial, a California-based team estimates 93 million US adults met criteria for semaglutide 2.4 mg and use could prevent 1.5 million incident cardiovascular events over a 10-year period.
Diabetes Dialogue: Implications of SELECT Trial and Brenzavvy on Cost Plus Drugs
August 15th 2023In this episode, hosts take time to break down the implications of two, potentially paradigm-shifting news in the announcement of the addition of bexagliflozin to the Cost Plus Drugs platform and topline data from the landmark SELECT trial.
Pharmacist-Led, Community-Led Programs Can Improve Health Literacy, with Clipper Young, PharmD, MPH
August 11th 2023In a Q&A, Clipper Young, PharmD, MPH, discusses the Pharm2Home Initiative based on his presentation from ADCES 2023 and describes the impact of community-driven, pharmacist-led interventions to improve health literacy in those with chronic disease.
Optimization of Deprescribing in Older Adults with Diabetes, with Joshua Neumiller, PharmD
August 9th 2023Joshua Neumiller, PharmD, takes part in a Q&A on the role of deprescribing in older adults with diabetes mellitus based on a presentation from the Association of Diabetes Care and Education Specialists 2023 annual meeting.
Endocrine Case Report: Confusion
August 2nd 2023This endocrine case report feature a woman with a history of diabetes, hypertension, and marijuana use in her mid 50s brought to the ED for confusion by her friend and neighbor who states that she has been like this for 3 days. Can you determine how best to proceed?